Design and validation of a population-based definition of the metabolic syndrome

Diabetes Care

Volumn 29, Issue 11, 2006, Pages 2420-2426

  Aguilar Salinas, Carlos A ^a   Rojas, Rosalba ^b   Gonzalez Villalpando, Clicerio ^c   Gómez Pérez, Francisco J ^a   Mehta, Roopa ^a   Olaiz, Gustavo ^b   Rull, Juan A ^a   Cox, David R ^d  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^c AMERICAN BRITISH COWDRAY MEDICAL CENTER   (Mexico)

^d Perlegen Sciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH STATISTICS; HEALTH SURVEY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MEXICO; NOMENCLATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PROGNOSIS;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEALTH SURVEYS; HUMANS; HYPERINSULINISM; INCIDENCE; MALE; METABOLIC SYNDROME X; MEXICO; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SEX DISTRIBUTION; URBAN POPULATION;

EID: 33845502777     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-0611     Document Type: Article

References (29)

1. Groop L, Orho-Melander M: The dysmetabolic syndrome. J Intern Med 250:105-120, 2001
2. Ford E, Giles W, Dietz W: Prevalence of the metabolic syndrome among US adults. JAMA 287:356-359, 2002
3. Meigs J: The metabolic syndrome: may be a guidepost or detour to preventing type 2 diabetes and cardiovascular disease. BMJ 327:61-62, 2003
4. Reaven GM: Insulin resistance, cardiovascular disease and the metabolic syndrome: how well do the emperor's clothes fit? Diabetes Care 27:1011-1012, 2004
5. Alberti FGMM, Zimmet PZ, the WHO Consultation: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med 15:539-553, 1998
6. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Cholesterol. JAMA 285:2486-2497, 2001
7. The International Diabetes Federation: The IDF consensus worldwide definition of metabolic syndrome[article online]. 2005. Available from http://www.idf.org/webdata/docs/MetSyndrome_FINAL.pdf. Accessed 3 May 2005
8. Sanchez-Castillo C, Velázquez-Monroy O, Berber A, Lara A, Tapia Conyer R, James P, the Encuesta Nacional de Salud 2000 Working Group: Anthropometric cutoff points for predicting chronic diseases in the Mexican National Health Survey 2000. Obes Res 11:442-451, 2003
9. WHO Expert Consultation: Appropriate body mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363:157-163, 2004
10. Liao Y, Kwon S, Shaughnessy S, Wallace P, Hutto A, Jenkins A, Klein R, Garvey WT: Critical evaluation of the Adult Treatment Panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 27:978-983, 2004
11. Deurenberg P, Yap M, van Staveren WA: Body mass index and percent body fat: a meta analysis among different ethnic groups. Int J Obes Relat Metab Disord 22:1164-1171, 1998
12. Ford ES: Risk for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. Diabetes Care 28:1769-1778, 2005
13. Tan CE, Ma S, Wai D, Chew SK, Tai ES: Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 27:1182-1186, 2004
14. Ford ES: Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 28:2745-2749, 2005
15. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, Valles V, Rios-Torres JM, Franco A, Olaiz G, Rull JA, Sepúlveda J: High prevalence of the metabolic syndrome in México. Arch Med Res 35:76-81, 2004
16. Aguilar-Salinas CA, Olaiz G, Valles V, Rios-Torres JM, Gomez-Perez FJ, Rull JA, Rojas R, Franco A, Sepúlveda J: High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J Lipid Res 42:1298-307, 2001
17. Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, Garcia E, Valles V, Rios-Torres JM, Franco A, Olaiz G, Sepúlveda J, Rull JA: Prevalence and characteristics of early-onset type 2 diabetes in Mexico. Am J Med 113:569-574, 2002
18. Valles V, Aguilar-Salinas CA, Gómez-Pérez FJ, Rios-Torres JM, Gomez-Perez FJ, Rull JA, Rojas R, Franco A, Sepúlveda J: Apolipoprotein B and A-I distribution in the Mexican urban adults: results of a nationwide survey. Metabolism 51:560-568, 2002
19. Meigs J, Williams K, Sullivan L, Hunt K, Haffner SM, Stern M, Gonzalez Villalpando C, Perhanidis J, Nathan D, D'Agostino R, D'Agostino R, Wilson P: Using metabolic syndrome traits for efficient detection of impaired glucose tolerance. Diabetes Care 27:1417-1426, 2004
20. Gonzalez-Villalpando C, Rivera-Martinez D, Cisneros-Castolo M, Gonzalez-Villalpando ME, Simon J, Williams K, Haffner S, Stern M: Seven-year incidence and progression of obesity: characterization of body fat pattern evolution in low-income Mexico City urban population. Arch Med Res 34:348-353, 2003
21. Hunt KJ, William K, Rivera D, O'Leary DH, Haffner SM, Stern MP, Gonzalez Villalpando C: Elevated carotid artery intima-media thickness levels in individual who subsequently develop type 2 diabetes. Arterioscler Thromb Vasc Biol 23:1845-1850, 2003
22. Han TS, Sattar N, William K, Gonzalez Villapando C, Lean ME, Haffner SM: Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 25:2016-2021, 2002
23. Grundy SM, Hansen B, Smith S, Cleeman JI, Kahn RA: Clinical management of metabolic syndrome. Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 109:551-556, 2004
24. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108:414-419, 2003
25. Wannamethee SG, Shaper G, Lennon L, Morris R: Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke and type 2 diabetes. Arch Intern Med 165:2644-2650, 2005
26. Wilson P, D'Agostino R, Parise H, Sullivan L, Meigs J: Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112:3066-3072, 2005
27. Hanley A, Karter A, Williams K, Festa A, D'Agostino R, Wagenknecht L, Haffner SM: Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome. Circulation 112:3713-3721, 2005
28. Malik S, Wong N, Franklin S, Kamath T, L'Italien G, Pio J, Rhys Willliam G: Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease and all causes in United States adults. Circulation 110:1245-1250, 2004
29. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM: Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 27:2676-2681, 2004